318 related articles for article (PubMed ID: 20975737)
1. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.
Roukos DH
Pharmacogenomics J; 2011 Apr; 11(2):81-92. PubMed ID: 20975737
[TBL] [Abstract][Full Text] [Related]
2. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care.
Roukos DH
Expert Rev Mol Diagn; 2010 Jan; 10(1):33-48. PubMed ID: 20014921
[TBL] [Abstract][Full Text] [Related]
3. Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks.
Roukos DH; Ziogas DE; Katsios C
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1187-95. PubMed ID: 20735306
[TBL] [Abstract][Full Text] [Related]
4. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.
Wang E; Zaman N; Mcgee S; Milanese JS; Masoudi-Nejad A; O'Connor-McCourt M
Semin Cancer Biol; 2015 Feb; 30():4-12. PubMed ID: 24747696
[TBL] [Abstract][Full Text] [Related]
5. Whole-exome sequencing reveals recurrent somatic mutation networks in cancer.
Liu X; Wang J; Chen L
Cancer Lett; 2013 Nov; 340(2):270-6. PubMed ID: 23153794
[TBL] [Abstract][Full Text] [Related]
6. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
7. Complete genome sequencing and network modeling to overcome trastuzumab resistance.
Roukos DH
Pharmacogenomics; 2010 Aug; 11(8):1039-43. PubMed ID: 20704462
[No Abstract] [Full Text] [Related]
8. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
9. Understanding genomic alterations in cancer genomes using an integrative network approach.
Wang E
Cancer Lett; 2013 Nov; 340(2):261-9. PubMed ID: 23266571
[TBL] [Abstract][Full Text] [Related]
10. Genome network medicine: innovation to overcome huge challenges in cancer therapy.
Roukos DH
Wiley Interdiscip Rev Syst Biol Med; 2014; 6(2):201-8. PubMed ID: 24318985
[TBL] [Abstract][Full Text] [Related]
11. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
[TBL] [Abstract][Full Text] [Related]
13. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.
Hamel S; Bouchard A; Ferrario C; Hassan S; Aguilar-Mahecha A; Buchanan M; Quenneville L; Miller W; Basik M
Breast Cancer Res Treat; 2010 Feb; 120(1):47-57. PubMed ID: 19301121
[TBL] [Abstract][Full Text] [Related]
14. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
15. Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.
Lee J; Ou SH
Discov Med; 2013 Aug; 16(86):7-14. PubMed ID: 23911227
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in molecular genetics of breast cancer.
Pavelić K; Gall-Troselj K
J Mol Med (Berl); 2001 Oct; 79(10):566-73. PubMed ID: 11692153
[TBL] [Abstract][Full Text] [Related]
18. Cancer omics: from regulatory networks to clinical outcomes.
Tang B; Hsu PY; Huang TH; Jin VX
Cancer Lett; 2013 Nov; 340(2):277-83. PubMed ID: 23201140
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.
Cronin M; Ross JS
Biomark Med; 2011 Jun; 5(3):293-305. PubMed ID: 21657839
[TBL] [Abstract][Full Text] [Related]
20. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
Biroccio A; D'Angelo C; Jansen B; Gleave ME; Zupi G
J Cell Physiol; 2005 Aug; 204(2):463-9. PubMed ID: 15685647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
